STOCK TITAN

Medigus: Revoltz Opens for Pre-Orders of its Revolutionary Micro Mobility EV

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary
Medigus Ltd. (Nasdaq: MDGS) announces the pre-order launch of PORTO, an innovative electric vehicle (EV) from its subsidiary, Revoltz Ltd. The pre-order launch is led by Revoltz Ltd., a company specializing in high-end, mini electric vehicles, bringing innovation and elevating single-rider transportation. The PORTO is designed for modern cities, combining long-range capability, robust design, and exceptional agility, marking a significant step in Revoltz's commitment to sustainable, efficient, and cutting-edge urban logistics solutions.
Positive
  • None.
Negative
  • None.

The announcement of pre-orders for the PORTO electric vehicle (EV) by Medigus Ltd.'s subsidiary, Revoltz Ltd., represents a strategic move within the EV market. The focus on high-end, mini electric vehicles for urban delivery solutions taps into the growing demand for sustainable transportation and the need for efficient logistics in densely populated areas. This segment is witnessing increasing competition and the success of the PORTO could hinge on its ability to differentiate itself through long-range capability, robust design and agility.

For stakeholders, the short-term implications include monitoring the market reception of the pre-order launch, which could serve as a leading indicator of product demand and potential revenue growth. In the long-term, the adoption rate of the PORTO and its operational performance will be critical in evaluating Medigus's ability to capture and maintain a significant share of the EV market, particularly in urban logistics. The environmental impact reduction claim also aligns with global sustainability trends, which could enhance the company's brand image and appeal to eco-conscious consumers.

Medigus Ltd.'s launch of the PORTO EV pre-orders through its subsidiary Revoltz Ltd. can be seen as a capital-intensive initiative with potential long-term financial implications. Investors should consider the capital allocation for research and development, production and marketing of the PORTO, as well as the partnership structure with Charging Robotics Ltd. and Fuel Doctor Holdings, Inc. The 19.9% holding by Charging Robotics suggests a strategic alliance that might provide synergies in charging solutions or technology integration.

It is essential to analyze the pre-order volume and the conversion rate to actual sales post-launch to assess the initial success and potential revenue impact. Additionally, the market's response to the PORTO's pre-order can influence Medigus's stock performance on the Nasdaq and potentially, Fuel Doctor Holdings's performance on the OTC Market. The financial health of Medigus and its ability to sustain investments in Revoltz without diluting shareholder value will be a key consideration for investors.

The emphasis on the PORTO's eco-friendliness and its role in reducing environmental impact reflects a broader industry trend towards sustainable urban mobility solutions. The EV market is increasingly influenced by environmental regulations and consumer preferences for green transportation options. Revoltz's commitment to innovation in single-rider transportation indicates a targeted approach to address urban congestion and pollution.

Analyzing the environmental benefits of the PORTO, such as its potential to lower carbon emissions compared to traditional delivery vehicles, is vital. The long-term success of the PORTO may depend on its environmental performance metrics, which can attract not only individual consumers but also commercial entities looking to reduce their carbon footprint. The integration of such vehicles into existing urban infrastructures and their acceptance by regulatory bodies will also be indicative of the PORTO's impact on sustainable urban development.

Secure your pre-order of the PORTO EV at: https://revoltzev.com/porto/

Tel Aviv, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced the launching of the pre-order of the PORTO, an innovative electric vehicle (EV) from its subsidiary, Revoltz Ltd.

The pre-order launch is led by Revoltz Ltd., which is 19.9% held by Charging Robotics Ltd., a wholly owned subsidiary of Fuel Doctor Holdings, Inc. (OTC: FDOC), a Delaware corporation listed on the OTC Market (67.15% owned by Medigus). Revoltz specializes in high-end, mini electric vehicles, bringing innovation and elevating single-rider transportation.

Revoltz will enable customers to secure their specifically designed PORTO during the launch period.

For further details, please visit: https://revoltzev.com/porto/

The PORTO is a leap forward in urban delivery solutions. Designed for the demands of modern cities, it combines long-range capability, robust design, and exceptional agility. The opening of pre-orders marks a significant step in Revoltz's commitment to offer sustainable, efficient and cutting-edge solutions for urban logistics.

By opening pre-orders for the PORTO, Revoltz is offering an exclusive opportunity to be among the first to experience this innovative delivery solution. The PORTO exemplifies Revoltz's dedication to eco-friendly transportation and a addresses urban, personal and commercial needs while also reducing environmental impact.

About Medigus

Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technology company focused on innovative growth partnerships, mainly in advanced medical solutions, digital commerce and electric vehicle markets. Medigus' affiliations in the medical solutions arena include ownership in Polyrizon Ltd. The Company’s affiliates in digital commerce include Gix Internet Ltd., Jeffs' Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle market, Charging Robotics Ltd. and Revoltz Ltd. are also part of the Company’s portfolio of technology solution providers. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Medigus’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release. For example, Medigus uses forward looking statement when describing PORTO’s impact on urban transportation.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, Medigus undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Medigus is not responsible for the contents of third-party websites.

Company Contact:

Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com

Investor Relations Contact:

Michal Efraty
Investor Relations, Israel
+972-(0)52-3044404
michal@efraty.com


Medigus Ltd. (Nasdaq: MDGS) announced the pre-order launch of PORTO, an innovative electric vehicle (EV) from its subsidiary, Revoltz Ltd.

The pre-order launch is led by Revoltz Ltd., a company specializing in high-end, mini electric vehicles, bringing innovation and elevating single-rider transportation.

The PORTO is designed for modern cities, combining long-range capability, robust design, and exceptional agility, marking a significant step in Revoltz's commitment to sustainable, efficient, and cutting-edge urban logistics solutions.

For further details and to secure a pre-order of the PORTO, visit: https://revoltzev.com/porto/
Medigus Ltd.

NASDAQ:MDGS

MDGS Rankings

MDGS Latest News

MDGS Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Israel
Pob 3030

About MDGS

medical device company focused on innovative endoscopic procedures and devices. medigus developed an entire endoscopic system for intraluminal treatment of gerd (gastroesophageal reflux disease), one of the most common chronic diseases in the western world. the endoscopic system for the treatment of gerd - the srs - combines a miniaturized video camera, a surgical stapler and ultrasonic sights for alignment in a single instrument. the srs system and its unique flexible endoscope allows gastroenterologists and surgeons to perform endoluminally a true partial anterior fundoplication, thereby revolutionizing the treatment of gerd by eliminating the need for open or laparoscopic surgery - the current standard practice for treating severe gerd. shifting the gerd treatment from surgery to an endoluminal procedure, without opening the abdominal cavity, is a revolution. in addition, medigus designs and manufactures endoscopy systems for partner companies based on its proprietary technologies,